| Hans-Günter Meyer-Thompson | Hepatitiden
New Safety Issues for Hepatitis C Antivirals
In October 2016 the FDA identified the first new major safety problem linked to the nine new direct- acting antiviral drugs for hepatitis C, including sofosbuvir (SOVALDI), ledipasvir-sofosbuvir (HARVONI), and simeprevir (OLYSIO). (Institute for Safe Medication Practices ISMP, Monitoring FDA MedWatch Reports, January 25, 2017 — New data from 2016 Q2)